De novo Synthesis and Memory

从头合成和记忆

基本信息

  • 批准号:
    10056993
  • 负责人:
  • 金额:
    $ 57.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-12-01 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary Memory is our most precious possession, yet we remain unable to prevent its loss in neurological diseases. Here we examine a fundamental property of memory, which is its dependence on rapid de novo protein synthesis, and identify pathways that contribute to normal memory and that underlie human memory loss. Dr. Worley's laboratory pioneered the discovery and analysis of cellular immediate early genes (IEGs) as effectors of protein synthesis-dependent memory, and has described mechanisms mediated by IEGs Arc, Homer 1a and NPTX2 at excitatory synapses that strengthen active synapses and weaken inactive synapses. Emerging concepts integrate their individual molecular and synaptic functions into a temporal program of sequential cellular and circuit adaptations that encode information. The process begins with Arc and Homer1a, which act cell-autonomously to control the synaptic expression of AMPA type glutamate receptors. A later process mediated by secreted NPTX2 acts non cell-autonomously to strengthen excitatory synapses on a specific class of inhibitory neurons that express parvalbumin. Studies from mouse models indicate that down regulation of NPTX2 results in increased neural activity that may occlude the ability of networks to encode information, as well as a propensity for activity-dependent pathology including seizures and Aß amyloid generation. Remarkably, aspects of this inhibitory network phase of information storage can be monitored in living human subjects. Secreted NPTX2 is detected in human CSF and is prominently down-regulated in neurological diseases in association with cognitive deterioration. We hypothesize that NPTX2 down-regulation provides a rational biomarker of cognitive status in human neurological disease and may be is causal for certain memory deficits. Basic studies will examine the unusual regulatory mechanisms that control NPTX2 expression and function, and identify processes that result in its down-regulation in human brain. We will also gain deeper insight into how IEGs, and NPTX2 in particular, contribute to memory using gain and loss of function approaches in in vivo models of activity-dependent network plasticity including hippocampal replay. Stable, long-term support will allow us to establish a multidisciplinary research program that leverages the strengths of the Neuroscience community at Johns Hopkins for basic studies, and the Clinical Departments of Neuropathology and Psychiatry at Johns Hopkins and Neurology at UC San Diego for translational aspects of disease research. These studies will establish a novel, rational, and translatable concept for why humans lose memory function in disease.
项目摘要 记忆是我们最宝贵的财富,但我们仍然无法阻止它在神经系统疾病中的丧失。 在这里,我们研究记忆的一个基本属性,即它对快速从头蛋白的依赖 合成,并找出有助于正常记忆和导致人类记忆丧失的途径。Dr。 沃利的实验室率先发现和分析了细胞即刻早期基因(IEGs)作为效应器 并描述了IEGS Arc,Hmer 1a和IEGS Arc,Hmer 1a和 NPTX2位于兴奋性突触,加强活跃的突触,削弱不活跃的突触。新兴 概念将它们各自的分子和突触功能集成到序列的时间程序中 编码信息的细胞和电路适配。这一过程始于Arc和Hmer 1a,它们起作用 细胞-自主控制AMPA型谷氨酸受体的突触表达。稍后的流程 由分泌的NPTX2介导的非细胞自主作用增强特定类别的兴奋性突触 表达小白蛋白的抑制神经元。来自小鼠模型的研究表明,向下调节 NPTX2导致神经活动增加,这可能会阻止网络编码信息的能力,因为 以及活动依赖的病理倾向,包括癫痫发作和淀粉样蛋白的生成。 值得注意的是,可以在活人身上监测到信息存储的这种抑制网络阶段的各个方面 研究对象。在人的脑脊液中检测到分泌型NPTX2,并在神经系统中显著下调 与认知退化有关的疾病。我们假设NPTX2下调提供了一个 人类神经系统疾病认知状态的合理生物标记物,可能是某些记忆的原因 赤字。基础研究将研究控制NPTX2表达和 功能,并确定导致其在人脑中下调的过程。我们还将获得更深的 深入了解IEG,特别是NPTX2是如何通过功能的获得和丧失来促进记忆的 活体模型中活动依赖的网络可塑性的方法,包括海马体回放。稳定, 长期的支持将使我们能够建立一个多学科的研究计划,利用 约翰霍普金斯大学神经科学界的基础研究,以及 约翰·霍普金斯大学的神经病理学和精神病学以及加州大学圣地亚哥分校的神经学,翻译方面 疾病研究。这些研究将建立一个新的、合理的、可翻译的概念来解释为什么人类会输 疾病中的记忆功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAUL F WORLEY其他文献

PAUL F WORLEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAUL F WORLEY', 18)}}的其他基金

Project 3: Precision biomarkers of Brain Health, Age-related Cognitive Impairment and AD
项目3:大脑健康、年龄相关认知障碍和AD的精准生物标志物
  • 批准号:
    10491880
  • 财政年份:
    2021
  • 资助金额:
    $ 57.31万
  • 项目类别:
Project 3: Precision biomarkers of Brain Health, Age-related Cognitive Impairment and AD
项目3:大脑健康、年龄相关认知障碍和AD的精准生物标志物
  • 批准号:
    10689324
  • 财政年份:
    2021
  • 资助金额:
    $ 57.31万
  • 项目类别:
Project 3: Precision biomarkers of Brain Health, Age-related Cognitive Impairment and AD
项目3:大脑健康、年龄相关认知障碍和AD的精准生物标志物
  • 批准号:
    10270197
  • 财政年份:
    2021
  • 资助金额:
    $ 57.31万
  • 项目类别:
Plasma Assays for NPTX2 in Alzheimer's Disease
阿尔茨海默病中 NPTX2 的血浆检测
  • 批准号:
    10325347
  • 财政年份:
    2021
  • 资助金额:
    $ 57.31万
  • 项目类别:
Research Education Component
研究教育部分
  • 批准号:
    10591559
  • 财政年份:
    2020
  • 资助金额:
    $ 57.31万
  • 项目类别:
Research Education Component
研究教育部分
  • 批准号:
    10374079
  • 财政年份:
    2020
  • 资助金额:
    $ 57.31万
  • 项目类别:
Rheb 1 and mTORC1 Signaling
Rheb 1 和 mTORC1 信号转导
  • 批准号:
    10404516
  • 财政年份:
    2018
  • 资助金额:
    $ 57.31万
  • 项目类别:
Rheb 1 and mTORC1 Signaling
Rheb 1 和 mTORC1 信号转导
  • 批准号:
    10171825
  • 财政年份:
    2018
  • 资助金额:
    $ 57.31万
  • 项目类别:
De novo Synthesis and Memory
从头合成和记忆
  • 批准号:
    10524027
  • 财政年份:
    2016
  • 资助金额:
    $ 57.31万
  • 项目类别:
De novo Synthesis and Memory
从头合成和记忆
  • 批准号:
    10307140
  • 财政年份:
    2016
  • 资助金额:
    $ 57.31万
  • 项目类别:

相似海外基金

Development of prevention of Alzheimer's disease using transgenic soybean expressing amyloid beta protein
使用表达β淀粉样蛋白的转基因大豆预防阿尔茨海默病的进展
  • 批准号:
    19K07989
  • 财政年份:
    2019
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Collaborative Research: Dynamics of surfactant - amyloid-beta protein interactions during self-assembly
合作研究:自组装过程中表面活性剂 - 淀粉样蛋白 - β 蛋白相互作用的动力学
  • 批准号:
    1802641
  • 财政年份:
    2018
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Standard Grant
Collaborative Research: Dynamics of surfactant - amyloid-beta protein interactions during self-assembly
合作研究:自组装过程中表面活性剂 - 淀粉样蛋白 - β 蛋白相互作用的动力学
  • 批准号:
    1802588
  • 财政年份:
    2018
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Standard Grant
Analysis of a new mechanism to specifically inhibit amyloid-beta protein production
特异性抑制β-淀粉样蛋白产生的新机制分析
  • 批准号:
    18K14883
  • 财政年份:
    2018
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Dynamics of surfactant - amyloid beta protein interactions during self-assembly
合作研究:自组装过程中表面活性剂-淀粉样β蛋白相互作用的动力学
  • 批准号:
    1802793
  • 财政年份:
    2018
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Standard Grant
Aggregation of amyloid-beta protein on size-controlled lipid nanoparticles
淀粉样β蛋白在尺寸控制的脂质纳米颗粒上的聚集
  • 批准号:
    16K18860
  • 财政年份:
    2016
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Structure and molecular interactions in aggregation of amyloid beta protein
β淀粉样蛋白聚集的结构和分子相互作用
  • 批准号:
    26860020
  • 财政年份:
    2014
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
A novel therapeutic strategy for Alzheimer's disease based on the promotion of clearance mechanism of amyloid beta protein
基于促进β淀粉样蛋白清除机制的阿尔茨海默病新治疗策略
  • 批准号:
    26670126
  • 财政年份:
    2014
  • 资助金额:
    $ 57.31万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Amyloid Beta-Protein: Wild Type and Familial Mutant Assembly and Inhibition
β-淀粉样蛋白:野生型和家族突变体的组装和抑制
  • 批准号:
    8728102
  • 财政年份:
    2013
  • 资助金额:
    $ 57.31万
  • 项目类别:
Amyloid Beta-Protein: Wild Type and Familial Mutant Assembly and Inhibition
β-淀粉样蛋白:野生型和家族突变体的组装和抑制
  • 批准号:
    9110110
  • 财政年份:
    2013
  • 资助金额:
    $ 57.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了